Roche and reMYND enter into a strategic alliance to develop treatments for Parkinson’s and Alzheimer’s disease

10-Sep-2010 - Roche and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting alpha-synuclein and tau toxicity. The collaboration will focus on two of reMYND’s pre-clinical small ...

Actavis plans to enter into Biosimilars

09-Sep-2010 - Actavis Group announced that it plans to enter into the field of biosimilars. Dr. Claudio Albrecht CEO of Actavis commented on the upcoming due diligence on Biopartners in Switzerland: “By entering into Biosimilars the generic companies gain access to a portfolio that requires a new approach to ...

PolyTherics moves lead candidate into development and manufacturing with DSM BioSolutions

09-Sep-2010 - DSM BioSolutions, DSM’s microbial fermentation CMO business unit and PolyTherics Limited announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN alpha-2a. PolyTherics has applied its HiPEG™ site-specific ...

Prima Biomed and Bioceros announce licensing agreement for Cripto-1 cancer immunotherapy treatment

09-Sep-2010 - Prima BioMed Ltd announced that its subsidiary company, Oncomab Pty Ltd has entered into a licensing agreement for the development of a Cripto-1 cancer monoclonal antibody (mAB) with Bioceros. The licensing agreement paves the way for the further development of Oncomab’s technology to create a ...

Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia

R&D operations in Zagreb fulfil Galapagos' growing R&D capacity requirements

09-Sep-2010 - Galapagos and GlaxoSmithKline announced they have reached an agreement for Galapagos to acquire GSK's state-of-the art research centre in Zagreb, Croatia. The arrangement, which is subject to closing conditions and is expected to be effective as of 9 September 2010, provides for ongoing ...

Pharma to Make the Private Public

09-Sep-2010 - Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save ...

BioFocus and Usher III Initiative, Inc. announce collaboration

08-Sep-2010 - BioFocus and the Usher III Initiative, Inc., announced today that they have embarked on a drug discovery project focused on Usher Syndrome Type III. Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated ...

Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan

08-Sep-2010 - Stallergenes S.A. has announced the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million ...

BioEquality: Improving the Safety of Gene Technologically Manufactured Biopharmaceuticals

07-Sep-2010 - Within the ZIM funded BioEquality project the Frauenhofer Institute SCAI, the A&M STABTEST GmbH and the MassMap GmbH & Co. KG will develop a software for the automated analysis of the quality of Biopharmaceuticals and the equivalence of Biosimilars. Since the market release of Humulin (human ...

Broadvector $8.5m IPO to develop prostate cancer and hip repair therapies

07-Sep-2010 - Broadvector Limited has lodged a prospectus with ASIC to raise up to $8.5 million to advance the clinical development of a new prostate cancer therapy and a second therapy that repairs the common problem of aseptic loosening of hip replacements. Each of these therapies is based upon gene-directed ...